The startup develops hard-shelled liposomes (HSL) that enable the targeted release of therapeutic molecules directly at disease sites, enhancing drug efficacy while minimizing side effects. This technology widens the therapeutic window of medications, providing clinicians with a more effective treatment option.
Funding
$9.3M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Current drug delivery methods often lack precision, leading to systemic exposure of therapeutic molecules and potential off-target side effects. This non-specific distribution limits the efficacy of treatments, especially for localized diseases, and necessitates higher drug dosages to achieve therapeutic concentrations at the disease site.
Solution
The company develops hard-shelled liposomes (HSL) designed for targeted drug delivery, enabling the release of therapeutic molecules directly at the site of disease. These HSLs enhance drug efficacy by concentrating the medication where it is needed most, while simultaneously minimizing exposure to healthy tissues and reducing the risk of adverse side effects. This targeted approach broadens the therapeutic window for various medications, providing clinicians with a more effective and safer treatment option.
Target Audience
The primary customers are clinicians and pharmaceutical companies seeking to improve drug delivery and enhance treatment efficacy while reducing side effects.
Features
- Hard-shelled liposomes for enhanced stability and targeted delivery
- Site-specific release of therapeutic molecules
- Minimized systemic exposure, reducing off-target effects